Published • loading... • Updated
High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
The patient showed rapid blood recovery and no product-related adverse events as Correctseq said the therapy met its primary efficacy endpoint.
- On Tuesday, June 2, 2026, CorrectSequence Therapeutics announced that the first sickle cell disease patient treated in China with CS-206 remained free of VOCs for more than 15 months following engraftment, achieving the primary efficacy endpoint.
- Sickle cell disease, a hereditary hemoglobin disorder, affects around 300,000 babies born annually worldwide. The 21-year-old patient from Nigeria had experienced recurrent severe VOCs prior to treatment.
- Correctseq utilizes a proprietary transformer Base Editor to edit the HBG1 promoter region, a method that avoids DNA double-strand breaks and offers a safer alternative to CRISPR-based gene-editing therapies.
- Within one month, HbF levels increased significantly while HbS levels declined substantially. Beginning at Month 3, the HbF-to-HbS ratio stabilized at approximately 6:4, with neutrophil engraftment observed by Day 13.
- Global recruitment for the CS-206 investigator-initiated trial is currently ongoing, while Correctseq's CS-101 has successfully cured more than ten thalassemia patients across China, Laos, Malaysia, and Pakistan.
Insights by Ground AI
20 Articles
20 Articles
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources20
Leaning Left5Leaning Right4Center6Last UpdatedBias Distribution40% Center
Bias Distribution
- 40% of the sources are Center
40% Center
L 33%
C 40%
R 27%
Factuality
To view factuality data please Upgrade to Premium
